Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) Return on Equity (2021 - 2025)

Historic Return on Equity for Silence Therapeutics (SLN) over the last 5 years, with Q3 2025 value amounting to 0.77%.

  • Silence Therapeutics' Return on Equity fell 1400.0% to 0.77% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.77%, marking a year-over-year decrease of 1400.0%. This contributed to the annual value of 0.58% for FY2024, which is 16000.0% up from last year.
  • Latest data reveals that Silence Therapeutics reported Return on Equity of 0.77% as of Q3 2025, which was down 1400.0% from 0.8% recorded in Q2 2025.
  • Silence Therapeutics' Return on Equity's 5-year high stood at 0.39% during Q2 2024, with a 5-year trough of 7.4% in Q1 2022.
  • Its 5-year average for Return on Equity is 2.1%, with a median of 1.58% in 2021.
  • In the last 5 years, Silence Therapeutics' Return on Equity surged by 47600bps in 2023 and then tumbled by -4100bps in 2025.
  • Silence Therapeutics' Return on Equity (Quarter) stood at 3.71% in 2021, then tumbled by -100bps to 7.4% in 2022, then surged by 64bps to 2.69% in 2023, then skyrocketed by 85bps to 0.41% in 2024, then plummeted by -88bps to 0.77% in 2025.
  • Its last three reported values are 0.77% in Q3 2025, 0.8% for Q2 2025, and 0.63% during Q1 2025.